Subcutaneous semaglutide, on the other hand, was more frequently used to replace a previous regimen including an insulin (prandial or basal or both), compared with oral semaglutide (10.2% and 4.2% of cases, respectively), but the difference did not reach statistical significance.
← all excerpts
Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
1
—
—